# Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Study · id `cardio:ct-nct05565976` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05565976](<https://clinicaltrials.gov/study/NCT05565976>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05565976

Browse, organ or system: Brain; Metabolism  
Browse, condition area: Stroke; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.

## Technical summary

Registry record NCT05565976. Randomized; triple masking; primary purpose prevention. Start 2020-08-01 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 270 participants (planned count; ClinicalTrials.gov record NCT05565976, source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)
- Started: 2020-08-01 (actual) (ClinicalTrials.gov record NCT05565976, source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05565976, source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)
- Completion: 2025-07-01 (anticipated) (ClinicalTrials.gov record NCT05565976, source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT05565976, source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05565976-2022-10-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
- Acronym: DECIST
- Condition: Stroke, Ischemic
- Condition: Mild Cognitive Impairment
- Condition: Dementia, Vascular
- Condition: Metabolic Syndrome
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Statins (Cardiovascular Agents)
- Intervention (Drug): Platelet Antiaggregant
- Intervention (Drug): Antidiabetic
- Lead sponsor: Jaime Daniel Mondragon
- Lead sponsor class: OTHER
- Collaborator: Hospital General León
- Collaborator class: UNKNOWN
- Collaborator: Hospital General de Zona IMSS N0. 21
- Collaborator class: UNKNOWN
- Collaborator: University Medical Center Groningen
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial (`cardio:pubmed-32115470`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d61dc76253e11f749dfbfeb67c3a75323b9fd896b57d4b2116d8de736a57a031
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
